Ivonescimab Shows Survival Benefit in Biliary Tract Cancer Trial — Summit Therapeutics Inc.

Event summary

Ivonescimab plus chemotherapy demonstrated statistically significant overall survival benefit compared to durvalumab plus chemotherapy in a Phase III trial for advanced biliary tract cancer.
The HARMONi-GI1 study, conducted by Akeso in China, met primary and key secondary endpoints, including progression-free survival and objective response rate.
Detailed results from the study are expected to be presented at an upcoming medical congress and published in a peer-reviewed journal.
Ivonescimab is currently investigational in Summit Therapeutics' license territories, including the United States and Europe.

The big picture

The positive results from the HARMONi-GI1 study position ivonescimab as a potential first-in-class therapy for advanced biliary tract cancer, a field with limited treatment options. This success builds on Akeso's strong clinical track record with ivonescimab in non-small cell lung cancer, highlighting the drug's versatility across different tumor types. The data could also intensify competition with established immunotherapies like durvalumab, particularly in the first-line setting for biliary tract cancer.

What we're watching

Regulatory Pathway: Whether the positive data will accelerate regulatory filings and approvals for ivonescimab in new indications beyond China.
Commercial Strategy: How Summit Therapeutics plans to leverage these results to expand ivonescimab's market potential in the United States and Europe.
Clinical Pipeline: The pace at which additional Phase III trials for ivonescimab in other cancer types will read out, potentially broadening its therapeutic reach.